Article

Diet-induced MASH liver fibrosis promoted by EphB2 can be targeted by small molecule tetramerization inhibitors

2025-11-20

Abstract excerpt

The EphB2 receptor tyrosine kinase is thought to participate in numerous fibroinflammatory disorders. In metabolic dysfunction-associated steatohepatitis (MASH), we find EphB2 becomes strongly overexpressed and overactive in hepatic stellate cells (HSCs) from humans with the disease and from mice fed liver-injuring high fat diets. Genetic deletion of EphB2 or inactivation of its tyrosine kinase catalytic domain su...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 57802230-6477-57b5-b469-8b2baddb27c8
DOI: 10.1101/2025.11.19.688968

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Diet-induced MASH liver fibrosis promoted by EphB2 can be targeted by small molecule tetramerization inhibitorsDOI 10.1101/2025.11.19.688968Read

Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitisSemantic proximity Read

GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHSemantic proximity Read

Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cellsSemantic proximity Read

Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialinSemantic proximity Read

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.Semantic proximity Read

Integrating Network Pharmacology and Experimental Validation to Elucidate Huaier in Attenuating Liver Fibrosis via the AKT Signaling PathwaySemantic proximity Read

A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.Semantic proximity Read

The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular CarcinomaSemantic proximity Read

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticlesSemantic proximity Read

Liver Fibrosis and Inflammation under the Control of ERK2.Semantic proximity Read

Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.Semantic proximity Read

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosisSemantic proximity Read